Navigation Links
Boehringer Ingelheim and Micromet Announce Global Collaboration for Multiple Myeloma BiTE Antibody
Date:5/5/2010

or cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 15 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development.

For more information please visit www.boehringer-ingelheim.com

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ingenuity Systems Announces Multi-Year Agreement With Boehringer Ingelheim
2. Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim
3. Boehringer Ingelheim and BioSpace Search for Scientists at Career Fair in Boston, Massachusetts
4. More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheims Flomax as First-Line Therapy
5. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
6. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
7. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
8. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
9. Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey
10. Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
11. Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... PALO ALTO, Calif. , Jan. 22. 2015  Varian Medical ... equipment and software, has been honored for its commitment to ... most sustainable companies. Varian is the highest ranked healthcare equipment ... ranking, announced today during the World Economic Forum at ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval ... for the use of Medtronic,s SynchroMed ® II ... for use with United Therapeutics, Remodulin ® (treprostinil) ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ...
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 On ... H.R. 83, the Omnibus and Continuing Resolution Appropriations Act ... a condition eligible to receive funding through the Congressionally ... of Defense (DoD). The Hydrocephalus Association (HA), working in ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... May 13 -, EMERYVILLE, Calif., May 12 Neurobiological,Technologies, ... its fiscal third quarter and the nine months ended March ... 2008 were $3.7 million,compared to $4.9 million for the same ... $5.9 million for the third,quarter of 2008 compared to $7.7 ...
... WaferGen Biosystems,Inc. (OTC Bulletin Board: WGBS), a ... and stem cell research systems,today announced that Mr. ... a corporate presentation at the Rodman & Renshaw,Fifth ... held May,19-20, 2008, at the Le Meridien Beach ...
... Host Investor Conference Call on Monday, May 12, 2008 at 8:30am ... ... May 9 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopharmaceutical company ... the treatment of life-threatening,diseases, including renal disease and cancer, today announced its ...
Cached Biology Technology:Neurobiological Technologies Reports Third Quarter Financial Results 2Neurobiological Technologies Reports Third Quarter Financial Results 3Neurobiological Technologies Reports Third Quarter Financial Results 4Neurobiological Technologies Reports Third Quarter Financial Results 5WaferGen to Present at the Rodman and Renshaw Fifth Annual Global Healthcare Conference 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 5
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to current ... enables HITLAB to conduct regulated smart device and smart ... safety and research quality. "HITLAB is determined ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel experience and ... Over the past decade, ePassports, biometric readers, and secure ... through border control via eGates and Automated Passport Control ... and land borders across the globe. ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... systems. Multimodal biometric systems utilize more than one characteristic ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... against HIV increases the risk of developing clinical West Nile ... January 9th in The Journal of Experimental Medicine. , The ... that encodes a protein called CCR5, which was identified in ... Individuals with two copies of this mutation (CCR5delta32) are ...
... Gene variants determine which humans and which chimpanzees can ... influence nutritional choices and ultimately their health, as well ... a way to live safely in their environments by ... conducted more 65 years ago by a team of ...
... and Michael Emerman and colleagues at the Fred Hutchinson Cancer ... humans may be impaired in the function of a recently ... as HIV. , One of the key components of ... gene was discovered because the version of TRIM5 possessed by ...
Cached Biology News:Genetic mutation linked to West Nile virus infection 2Research updates 65-year-old genetic discovery 2Research updates 65-year-old genetic discovery 3
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
Anti-DNA Polymerase a, Human Description: 50 l Research Focus: cancer & cell proliferation Storage: 4C Shipping Temperature: 4C...
Vitronectin Immunogen: Purified, full length, native human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... microcapillary flow cytometry accessible to anyone in ... appreciate the latest addition to Guavas on-demand ... surprising affordable, and very compact for higher ... features as absolute cell counts, 6 parameters ...
Biology Products: